Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial › Research Explorer

DOI

https://doi.org/10.1016/S2665-9913(20)30341-6
Final published version
https://doi.org/10.1016/S2665-9913(20)30341-6
Final published version

Matthias Busch
Sjoerd A. M. E. G. Timmermans
Marcel C. G. van de Poll
Iwan C. C. van der Horst
Martin Witzenrath
Simon Rueckinger
Korinna Pilz
Ren-Feng Guo
Leo Heunks
Pieter van Paassen
Niels C. Riedemann

Original language	English
Pages (from-to)	e764-e773
Journal	The Lancet Rheumatology
Volume	2
Issue number	12
Early online date	2020
DOIs	https://doi.org/10.1016/S2665-9913(20)30341-6 https://doi.org/10.1016/S2665-9913(20)30341-6
Publication status	Published - Dec 2020

ID: 13866393